ES2191722T3 - Anticuerpo monoclonal especifico del pd-ecgf/timidina fosforilasa. - Google Patents

Anticuerpo monoclonal especifico del pd-ecgf/timidina fosforilasa.

Info

Publication number
ES2191722T3
ES2191722T3 ES95941870T ES95941870T ES2191722T3 ES 2191722 T3 ES2191722 T3 ES 2191722T3 ES 95941870 T ES95941870 T ES 95941870T ES 95941870 T ES95941870 T ES 95941870T ES 2191722 T3 ES2191722 T3 ES 2191722T3
Authority
ES
Spain
Prior art keywords
human
monoclonal antibody
growth factor
timidina
fosforilasa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95941870T
Other languages
English (en)
Inventor
Kazutaka Miyadera
Yuji Yamada
Yuji Takebayashi
Shin-Ichi Akiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2191722T3 publication Critical patent/ES2191722T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20Immunohistochemistry assay

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

UN ANTICUERPO MONOCLONAL CONTRA UN PEPTIDO EL CUAL SE HALLA EN LA FOSFORILASA DE TIMIDINA HUMANA Y EN EL FACTOR DE CRECIMIENTO CELULAR ENDOTELIAL VASCULAR QUE SE ORIGINA EN LAS PLAQUETAS HUMANAS Y QUE CONTIENE SECUENCIAS DE AMINOACIDOS DE SEQ IDNOS:1 Y 2, Y UN METODO DE INMUNOENSAYO DE LA FOSFORILASA DE TIMIDINA HUMANA Y/O FACTOR DE CRECIMIENTO CELULAR ENDOTELIAL VASCULAR QUE SE ORIGINA EN LAS PLAQUETAS HUMANAS USANDO ESTE ANTICUERPO MONOCLONAL. EL ANTICUERPO MONOCLONAL RECONOCE LA FOSFORILASA DE TIMIDINA HUMANA Y EL FACTOR DE CRECIMIENTO CELULAR ENDOTELIAL VASCULAR QUE SE ORIGINA EN LAS PLAQUETAS HUMANAS Y ES UTIL EN LA DIAGNOSIS Y TRATAMIENTO DE VARIOS TUMORES, METASTASIS DE LOS MISMOS, ENFERMEDADES ACOMPAÑADAS POR VASCULARIZACION ANORMAL, ETC.
ES95941870T 1994-12-28 1995-12-25 Anticuerpo monoclonal especifico del pd-ecgf/timidina fosforilasa. Expired - Lifetime ES2191722T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32732894A JP3268147B2 (ja) 1994-12-28 1994-12-28 モノクローナル抗体

Publications (1)

Publication Number Publication Date
ES2191722T3 true ES2191722T3 (es) 2003-09-16

Family

ID=18197918

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95941870T Expired - Lifetime ES2191722T3 (es) 1994-12-28 1995-12-25 Anticuerpo monoclonal especifico del pd-ecgf/timidina fosforilasa.

Country Status (8)

Country Link
US (1) US5798213A (es)
EP (1) EP0749981B1 (es)
JP (1) JP3268147B2 (es)
AT (1) ATE231167T1 (es)
AU (1) AU4315396A (es)
DE (1) DE69529405T2 (es)
ES (1) ES2191722T3 (es)
WO (1) WO1996020217A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025575A1 (en) * 2001-09-17 2003-03-27 Board Of Regents, The University Of Texas System Methods and compositions involving thymidine phosphorylase as a marker for hiv infection, aids progression, and drug resistance
EP3067698A1 (en) * 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Pd-ecgf as biomarker of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227302A (en) * 1988-12-20 1993-07-13 Ludwig Institute For Cancer Research DNA encoding platelet derived endothelial cell growth factor (PD-ECGF)
CA2005600A1 (en) * 1988-12-20 1990-06-20 Cal-Henrik Heldin Endothelial cell growth factor

Also Published As

Publication number Publication date
EP0749981B1 (en) 2003-01-15
AU4315396A (en) 1996-07-19
DE69529405T2 (de) 2003-10-30
JPH08183800A (ja) 1996-07-16
DE69529405D1 (en) 2003-02-20
US5798213A (en) 1998-08-25
JP3268147B2 (ja) 2002-03-25
EP0749981A1 (en) 1996-12-27
ATE231167T1 (de) 2003-02-15
EP0749981A4 (en) 2000-03-08
WO1996020217A1 (en) 1996-07-04

Similar Documents

Publication Publication Date Title
RU2012102323A (ru) Способ лечения ревматоидного артрита посредством лекарственного препарата на основе выделенного человеческого антитела или его антигенсвязывающего фрагмента
BR9808998A (pt) Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
BR9811260A (pt) Pequenas moléculas úteis no tratamento de doença inflamatória
DE69941214D1 (de) DIAGNOSE, VORBEUGUNG UND BEHANDLUNG VON ULCERATIVER COLITIS UND DEREN SUBTYPEN UNTER VERWENDUNG MIKROBIELLER UC pANCA ANTIGENE
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ATE419275T1 (de) Antikörper gegen vla-4
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
CY1105212T1 (el) Αντισωματα αντι-april και κυτταρα υβριδωματος
PT1353689E (pt) Composicoes imunizantes e metodos de utilizacao
ATE186646T1 (de) Impfstoff gegen die lyme-krankheit
ES2140468T3 (es) Material hidrofilo y membrana semipermeable fabricada a partir del mismo.
Siedlarl et al. The M-DC8-positive leukocytes are a subpopulation of the CD14+ CD16+ monocytes
Ryan et al. Coagulation and the expression of cell‐mediated immunity
ES2080800T3 (es) Polipeptidos y analogos de polipeptidos con actividad inhibitoria frente a la elastasa humana.
ES2127940T3 (es) Bloqueo de la adhesion de germenes a celulas humanas.
CY1111509T1 (el) Ενωσεις με ιδιοτητες απελευθερωσης αυξητικης ορμονης
FR2806739B1 (fr) Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
DE69104602D1 (de) Stressprotein aus bakterien.
FI953093A0 (fi) Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä
FI885454A0 (fi) Administrationssystem, som laongsamt frigoer substituerade dihydropyridiner.
ES2191722T3 (es) Anticuerpo monoclonal especifico del pd-ecgf/timidina fosforilasa.
ZA954430B (en) Novel elastase inhibitors
ES2057579T3 (es) Peptidos e1 y c de rubeola.
ES2052482T3 (es) Inhibidor de la proliferacion de celulas endoteliales.